NTCP gene polymorphisms and hepatitis B virus infection status in a Ghanaian population by Nyarko, Eric et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
7-3-2020 
NTCP gene polymorphisms and hepatitis B virus infection status 
in a Ghanaian population 
Eric Nyarko 
Christian Obirikorang 
W. K.B.A. Owiredu 
Evans Asamoah Adu 
Emmanuel Acheampong 
Edith Cowan University, e.acheampong@ecu.edu.au 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Medicine and Health Sciences Commons 
10.1186/s12985-020-01376-0 
Nyarko, E., Obirikorang, C., Owiredu, W. K. B. A., Asamoah, E. A., Acheampong, E., Aidoo, F., ... & Asare-Anane, H. 
(2020). NTCP gene polymorphisms and Hepatitis B virus infection status in a Ghanaian population. Virology 
Journal, 17, Article 91. https://doi.org/10.1186/s12985-020-01376-0 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/8581 
Authors 
Eric Nyarko, Christian Obirikorang, W. K.B.A. Owiredu, Evans Asamoah Adu, Emmanuel Acheampong, 
Freeman Aidoo, Emmanuel Ofori, Bright Selorm Addy, and Henry Asare-Anane 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/8581 
RESEARCH Open Access
NTCP gene polymorphisms and hepatitis B
virus infection status in a Ghanaian
population
Eric Nyarko1, Christian Obirikorang1*, W. K. B. A. Owiredu1, Evans Asamoah Adu1, Emmanuel Acheampong1,4,
Freeman Aidoo1, Emmanuel Ofori1, Bright Selorm Addy3 and Henry Asare-Anane2
Abstract
Background: SLC10A1 gene codes NTCP, a receptor through which the hepatitis B virus (HBV) gets access into
hepatocytes - a stage of the viral cycle necessary for replication. Polymorphism variants of SLC10A1 play roles in
HBV infection, viral clearance, treatment outcome, and complications, in diverse ethnic groups and countries.
However, no such study has been conducted in the Ghanaian population, a country with HBV endemicity.
Therefore, an exploratory study was conducted to investigate the presence of three (3) single nucleotide
polymorphisms (SNPs) in the SLC10A1 gene (rs2296651, rs61745930, and rs4646287) and assessed the risk of HBV
infection among the Ghanaian population.
Method: Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to
determine the presence of the SNPs among 292 participants comprising 146 HBV infected persons as case-subjects
and 146 HBV non-infected persons as control-subjects.
Results: The minor allele frequency (T) of rs2296651 was present in a significantly high proportion of cases
compared with the control group (11.6% vs. 3.1%, p < 0.0001). The homozygote recessive variant of rs61745930 was
present in 2.7% of the control group and 5.5% of the case group. Moreover, the minor allele frequencies of
rs4646287 were 9.3 and 8.2% among the control and the case group, respectively (p = 0.767). Under the dominant
(CC) genetic model of inheritance, rs2296651 was found to be protective of HBV infection [OR = 0.18 (0.07–0.44)],
whereas under the co-dominant and additive model, rs2296651 was a potential risk factor for HBV infection [OR =
5.2 (95%CI: 2.1–12.8); 3.5 (95%CI: 1.6–7.6], respectively. Variants of rs61745930 and rs4646287 were not associated
with HBV infection (p > 0.05). Polymorphisms in SLC10A1, however, did not show any significant association with
HBV infectivity (p > 0.05).
Conclusion: The study highlights some polymorphism proof that variants rs2296651, rs61745930, and rs4646287
exist in HBV-infected individuals in Ghana. Although variant rs2296651 was found to be associated with HBV
infection, this association warrants more studies. Polymorphisms in SLC10A1 were not associated with HBV
infectivity among the Ghanaian population. Further investigation is warranted to assess the offensive role of the
relationship between rs2296651 and HBV infectivity.
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Introduction
The prevalence of hepatitis B virus (HBV) infection in
regions of high endemicity ranges from 6 to 8%; in
Africa, prevalence rates of 10–15% have been reported
[1, 2]. Within the adult population in Ghana, prevalence
rates between 10 and 13% have been recorded across the
ten regions with a national average rate of 12.3% [3],
which is about 50% higher than the current global aver-
age. This predisposes at least 1/10th of every Ghanaian
adult to the risk of later suffering or even dying from
HBV- associated complications such as cirrhosis or
Hepatocellular carcinoma (HCC) [4, 5]. HBV infection,
progression, and complications are affected by factors
such as genes, race, gender, age, and expression of some
biomolecules such as CD4+ T-helper cells [6]. Spontan-
eous clearance of HBV infection is associated with vigor-
ous polyclonal and multi-specific CD4+T-helper cell
response, compared to the weak responses observed in
persistent or chronic infections [7]. Solute carrier family
10 A1 (SLC10A1) gene-coded Na+-taurocholate co-
transporting polypeptide (NTCP) is another molecule
that influences the outcome of HBV infection. It is a
protein receptor through which the HBV gets access
into the hepatocytes, a stage of the viral cycle necessary
for replication [8, 9]. Thus, NTCP could represent a mo-
lecular and pharmacologic target for treatment and
prevention.
With the high risk of HBV infection and its associated
end-stage liver complications, the lack of a cure for HBV
infection, high treatment cost [10, 11], low long term
benefits and high toxicity associated with interferon, nu-
cleoside and nucleotide therapies; new treatments and
methods targeting different molecules are warranted.
Single nucleotide polymorphic (SNP) variants of the
NTCP gene – SLC10A1 such as rs7154439, rs4646287
[4, 12, 13], rs2296651 and rs61745930 [14–16] is associ-
ated with HBV persistent infection (chronicity), expres-
sion of HBeAg and viral clearance among different
ethnic groups and countries. The polymorphic SNP vari-
ants in the Ghanaian population or responsible for any
of the HBV infection status are non-existent. Therefore,
this explorative study was conducted to determine the
presence three (3) SNPs in the SLC10A1 gene
(rs2296651, rs61745930, and rs4646287) and the risk of
HBV infection among the Ghanaian population.
Methods
Study design and participant selection
This was a case-control study. Two hundred and ninety-
two (292) participants comprising 146 HBV infected per-
sons as cases (excluding active hepatitis B cases) and 146
apparent healthy HBV non-infected persons as controls
were recruited from the Greater Accra Region of Ghana
All the participants selected were Ghanaians by birth be-
tween 18 and 65 years of age.
Sample size justification
The sample size for the study was calculated using the
Cochran–Armitage trend tests [17]. By considering the
additive genetic model at a case: control ratios of 1:1,
the rare allele frequency (0.079) of the most replicated
SNP (rs2296651), and a national HBV average preva-
lence of 12.3% [3], the sample size needed to achieve the
prespecified 0.05 α-level and a power 80 for a two-sided
trend test was 348 (174 cases vs 174 controls). The total
response rate of the participants was approximately
84.0% (292/348). The final population of the study con-
stituted 292 participants comprising of 146 cases and
146 controls.
Sample collection, preparation, biochemical analysis, and
DNA isolation
Nine (9) millilitres of venous blood was drawn from each
participant into a 3ml serum separator gel tube (SST) and
two 3ml EDTA tubes; thus, one for haematology and the
other for DNA extraction. This was done to avoid con-
tamination. The SST sample was allowed to clot and cen-
trifuged at 2500 g for 7mins to obtain serum and
preserved between − 16 to − 20 °C till assayed. Mindray 5-
parts hematology analyzer (Mindray, Shenzhen-China,
2013) was used to quantify blood hemoglobin, blood cells
and other cellular indices one EDTA sample, using the
impedance, flow cytometry, and vis -spectrophotometry
methods depending on the analyte or index (Mindray,
2013, 2018). HumaStar 200 Clinical chemistry analyzer
(Human Diagnostics worldwide, Germany, 2014) was used
to quantify the concentrations of total and direct bilirubin,
total protein, albumin; and the activity of the enzymes:
alanine aminotransferase (ALT), aspartate aminotransfer-
ase (AST), gamma-glutamyl transferase (ϒGT) and alka-
line phosphatase (ALP) (Human Diagnostics worldwide,
Germany, 2014, 2018). Genomic (g) DNA was isolated
from the other EDTA anticoagulated sample as described
by Suguna, et al. [18], and preserved below − 80 °C until
genotyped.
Profiling of HBV antigens and HBV -host antibodies
The commercial Clinogen HBV-5 card was used to
screen for the presence of two (2) HBV viral antigens
and three (3) host antibodies using colloidal gold and
membrane chromatography technology (Clinogen Diag-
nostics, Japan) after ‘running’ HBV profile on ELISA-
confirmed controls previously obtained from the Nogu-
chi Memorial Institute for Medical Research (NMIMR),
Legon, Accra. HBsAg, HBeAg, and HBsAb were
screened for with the Immunochromatographic (dual-
antibody sandwich) principle, and the HBeAb and
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HBcAb were screened for by the neutralization competi-
tive inhibition principle (Clinogen Diagnostics, Japan;
Clinogen Diagnostics, UK).
Primer design
Primers spanning each of the SNP variants (rs2296651,
rs61745930, and rs4646287) were designed using the
NCBI Primer-BLAST software and the results shown in
Table S1 (https://www.ncbi.nlm.nih.gov/tools/primer-




To detect the presence of the rs2296651 (about 200 bp,
80), rs61745930 (about 400 bp, 250 bp), and rs4646287
(about 140 bp, 250) fragments, a 25 μL PCR reaction vol-
ume consisting of 8.5 μL nuclease-free water, 1 μL
(10 μM) each of forward and reverse primers, 12.5 μL of
One Taq 2x PCR Master mix (New England BioLabs
(NEB), USA) and 2 μL of the isolated genomic DNA was
prepared. Nuclease free water was used in place of the
gDNA in the negative control. PCR amplification was
done using the Applied Biosystems thermal cycler
(Fisher Scientific, USA). Denaturation was completed at
940 C for 3 mins (initial) and 940 C for 30 s (on rest).
Annealing conditions for rs2296651, rs61745930 and
rs4646287 were 580 C (30 s), 59.50 C (35 s) and 60.00 C
(30 s), respectively. Initial and final extension were com-
pleted at 720 C (30 s) and 720 C (10 mins), respectively.
The denaturation, annealing and extension steps were
done for 35 cycles, and the hold after the final extension
was at 4 °C.
Restriction digestion
The optimal enzyme concentration was prepared with
the appropriate assay buffer containing 1 μg of substrate
DNA according to Manufacturer’s instructions. Controls
were included to ensure there was no contamination or
unspecific product obtained. To complete the genotyp-
ing of rs2296651, 15 μL of the PCR product was added
to 0.2 μL of HphI enzyme (NEB, USA) and dissolved in
1.5 μL of NEB buffer and 3.3 μL of nuclease-free water,
and incubated at 37 0 C for 11 min for the enzyme diges-
tion of the PCR product. Similarly, 15 μL of the PCR
product was either added to 0.2 μL of BsaBI or 0.2 μL of
Taq I enzymes (NEB, USA) and dissolved in 1.5 μL of
NEB buffer and 3.3 μL of nuclease-free water and incu-
bated at 60 0 C for 60 min (1 h) for the enzyme digestion
of either rs61745930 or rs4646287.
Product visualization
The digested fragments were separated with a 2.5%
EtBr- incorporated agarose gel at 100 V, 2A for 90 min,
and using the Quick-Load purple 100 bp DNA Ladder
(NEB, USA) as the molecular marker (MM) and visualized
under UV trans-illuminator. The genotypes were deter-
mined according to the band patterns/sizes and in com-
parison, to the molecular marker (MM) as shown in the
supplementary figures. Figure S1, Figure S2 and Figure S3
show the gel bands for the SNP rs2296651, rs61745930,
and rs4646287, respectively.
Statistical analysis
Results obtained were entered into the Statistical Pack-
age for the Social Sciences (SPSS), coded, and analyzed
using this SPSS (version 23.0). Frequencies were used to
represent categorical data and compared using Chi-
Square test analysis to compare the genotype and allele
frequencies between the groups. Skewed data were com-
pared using the Man-Whitney Test. Normally distrib-
uted data were represented with mean ± standard
deviation and compared between groups using the T-
test. To test for associations between HBV and every
single SNP, logistic regression models were fitted, in
which each SNP was presented as a predictor variable
whose values were equal to the number of copies of the
minor allele (0, 1, 2) in an additive model, or presence of
at least one copy of the minor allele (0, 1) in a dominant
model or presence of two copies of the minor allele (0,
1) in a recessive model. Sex, age and family history of
HBV status were included as covariates in the fitted
model. The structure of the model was represented as:
Logit [pr(D = 1)] = α + β 1 G.
Where D denotes HBV phenotype; G denotes SNP
coded as an additive, dominant or recessive; β denotes
the corresponding coefficient for each variable in the
model, and its exponential is the corresponding odds ra-
tio. A P-value of less than 0.05 was considered statisti-
cally significant.
Results
Table 1 shows the comparison of age, gender, biochem-
ical indices between cases and controls. The male and
female participants were equivalently distributed among
cases and controls (p = 0.193). Total protein, direct
bilirubin, ALT, ALP and de-Ritis ratio did not show any
significant differences between cases and control partici-
pants (p > 0.05). However, total bilirubin (p = 0.002), in-
direct bilirubin (p < 0.0001), and AST (p = 0.007) were
significantly higher in cases compared with controls. On
the other hand, albumin (p = 0.010) and GGT (p = 0.042)
were significantly higher in controls compared with
cases. The aspartate aminotransferase-to-platelet ratio
index (APRI index) (p = 0.003), fibrosis index based on
four factors (FIB-4) (p = 0.009) and RDW-to-platelet ra-
tio (RPR) (p < 0.0001) were significantly higher in the
case-subjects compared to control subjects. Table S2
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shows the measured hematological parameters among
cases and control subjects. Apart from RBC count,
MCV, PCT, and hematocrit level (p > 0.05), cases and
control participants significantly differed in terms of
measured hematological parameters.
The genotype and allele frequencies of SLC10A1 gene
polymorphism were compared between cases and con-
trol participants (Table 2). The minor allele frequency
(T) of rs2296651 was presenting in a significantly high
proportion of cases compared with the control group
(0.116 vs 0.031, p < 0.0001). Also, the heterozygote
(18.5% vs 6.2%, p = 0.001) and homozygote recessive
(3.4% vs 0%, p = 0.025) variants of rs2296651 were
present in significantly higher proportions of the case
group than the control group, respectively. The homozy-
gote recessive variant of rs61745930 was present in 2.7%
of the control group and 5.5% of the case group. More-
over, the minor allele frequencies of rs4646287 were 9.3
and 8.2% among the control and the case group, respect-
ively (p = 0.767) (Table 2).
Table S3 shows the re-categorised into HBeAg positive
(active) and HBeAg negative (inactive) based on HBV
antigen/antibody profiling. The results indicated that
39.0% were active CHB cases whereas 61.0% were in-
active CHB cases.
The genotype and allele frequencies of SLC10A1 gene
polymorphism in active CHB and inactive CHB cases
are shown in Table 3. There were no significant
differences in allele and genotype frequencies among
HBeAg positive and HBeAg negative cases (p > 0.05)
Table 3.
The association between SLC10A1 variants and HBV
infection was compared under the recessive, dominant,
co-dominant and additive model of inheritance. Under
the dominant model, rs2296651 was found to be protect-
ive of HBV infection, whereas, under the co-dominant
and additive model, rs2296651 was a risk factor for HBV
infection (Table 4). Polymorphisms in rs61745930 and
rs4646287 were not significantly associated with HBV
infection under any of the models (Table 4).
Discussion
Several studies have reported the presence of SLC10A1
rs2296651, rs61745930, and rs4646287 SNP variants
among persons with HBV infection (4, 14, 24). Thus, we
determined the association between 3 SNPs in the
SLC10A1 gene (rs2296651, rs61745930, and rs4646287)
and the risk of HBV infection among the Ghanaian
population. Our results indicated that the MAF of
rs2296651 was 3.1% among HBV uninfected population
and 11.6% among HBV infected population. These find-
ings are similar to those reported among Korean (3.1%)
and Chinese-Americans (7.5%) populations [14]. Also,
similar findings have been replicated among Chinese
and Vietnamese in a study by Wang, et al. [13]. More-
over, Li, et al. [15] reported a 4.4% MAF of rs2296651







Male 68 (46.6) 57 (39.0)
Female 78 (53.4) 89 (61.0)
Age (years) 31.3 ± 10.0 30.6 ± 8.1 0.542
Total Bilirubin (μmol/L) 12.73 ± 5.29 14.89 ± 6.56 0.002
Direct Bilirubin (μmol/L) 6.59 ± 3.54 6.44 ± 3.22 0.700
Indirect Bilirubin (μmol/L) 6.08 ± 3.27 8.13 ± 4.50 < 0.0001
Total protein (g/L) 72.35 ± 7.52 70.83 ± 9.97 0.141
Albumin (g/L) 41.69 ± 5.53 39.72 ± 7.35 0.010
ALT (U/L 26.42 ± 11.79 27.33 ± 13.59 0.540
AST (U/L) 27.14 ± 13.30 30.35 ± 19.10 0.007
GGT (U/L) 33.37 ± 16.99 27.72 ± 12.73 0.042
ALP (U/L) 159.7 ± 55.8 159.0 ± 53. 0.914
De Ritis ratio 1.0 (0.80–1.26) 1.03 (0.76–1.47) 0.631
APRI index 0.30 (0.20–0.43) 0.37 (0.25–0.50) 0.003
FIB-4 0.68 (0.49–1.05) 0.80 (0.60–1.18) 0.009
RPR 0.06 (0.04–0.07) 0.07 (0.06–0.10) < 0.0001
Data is presented as means ± standard deviation. Variables with the superscript “a” were presented as frequency and subgroup proportions. ALT Alanine
aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase, APRI index Aspartate aminotransferase-to-platelet ratio index, FIB-4 fibrosis
index based on four factors, RPR RDW-to-platelet ratio, P < 0.05 is considered statistically significant
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Table 3 Genotype, allele frequencies of SLC10A1 gene polymorphism in active and inactive cases
SNP Inactive CHB cases (n = 89) Active CHB cases (n = 57) †P-value
N (%) Allele frequency N (%) Allele frequency
C T C T
rs2296651 0.882 0.118 0.860 0.140 0.240
CC 72 (80.9) 42 (73.7)
CT 13 (14.6) 14 (24.6)
TT 4 (4.5) 1 (1.8)
HWE-P‡ 0.123 0.112
rs61745930 0.044 0.956 0.035 0.965 0.382
TT 85 (95.5) 53 (93.0)
CT 0 0
CC 4 (4.5) 4 (7.0)
HWE-P‡ 0.013 0.009
rs4646287 0.916 0.084 0.912 0.088 0.374
CC 76 (85.4) 47 (82.5)
CT 11 (12.4) 10 (17.5)
TT 2 (2.2) 0
HWE-P‡ 0.615 0.821
HWE-P Hardy-Weinberg equation p-values, †P-values represents the chi-square test to compare genotype frequency between case-and control -subjects. P-values
for chi-squared test for variant allelic frequency based on HWE, p < 0.05 depicts it not consistent with HWE
Table 2 Genotype, allele frequencies of SLC10A1 gene polymorphism in the study participants
SNP Controls (n = 146) Cases (n = 146) †P-value
n (%) Allele frequency n (%) Allele frequency
C T C T
rs2296651 0.969 0.031 0.884 0.116 < 0.0001
CC 137 (93.8) 114 (78.1) 0.0001
CT 9 (6.2) 27 (18.5) 0.001
TT 0a 5 (3.4) 0.025
HWE-P‡ 1.00 0.112
rs61745930 0.014 0.986 0.028 0.972 0.238
TT 142 (97.3) 138 (94.5) 0.228
CT 0 0 –
CC 4 (2.7) 8 (5.5) 0.228
HWE-P‡ 0.003 0.009 0.888
rs4646287 0.907 0.093 0.918 0.082 0.767
CC 120 (82.2) 123 (84.2) 0.648
CT 24 (16.4) 21 (14.4) 0.636
TT 2 (1.4) 2 (1.4) 1.00
HWE-P‡ 0.763 0.549
Cases: HBV seropositive, Controls: HBV seronegative, HWE-P Hardy-Weinberg equation p-values, †P-values represents the chi-square test to compare genotype
frequency between case-and control -subjects. P-values for chi-squared test for variant allelic frequency based on HWE, p < 0.05 depicts it not consistent
with HWE
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among the Chinese Han population. In a more recent
study among Vietnamese, the rs2296651 variant was re-
ported in an average of 6% of the population, with a T
minor allele frequency of 3% [19].
Also, the distribution of the MAF of rs61745930 and
rs4646287 were 1.4 and 9.3% among HBV uninfected
population, and 2.8 and 8.2% among HBV infected
population. Variants of rs4646287 had the highest fre-
quency among the study participants, with about 16.4
and 1.4% of the Ghanaian HBV uninfected population
carrying the codominant (CT) and recessive (TT) vari-
ants, respectively. Lower frequencies of the variant than
these were observed among the Chinese Han [20] and
Chinese [21] population. Also, Chuaypen, et al. [22] re-
ported rs4646287 average MAF of 17.3% among the Thai
population with CT and TT genotype frequencies of 16
and 1.3% respectively and the T minor allele was found to
be 9.3%. These findings indicate that the rs2296651,
rs61745930, and rs4646287 SLC10A1 polymorphisms -its
genotypes and alleles- are widely distributed among Asians
and the Ghanaian population. However, some studies have
reported the absence or low prevalence of these SLC10A1
SNP variants in Caucasians [23]. Thus, replication studies
among a wider population of Ghanaians and the entire of
Africa are warranted since these countries represent HBV
endemic territories.
We observed that variants of rs2296651 were associ-
ated with the risk of HBV infection. However, the associ-
ation was independent of HBV infectivity. Under the
recessive, additive and codominant model of inheritance,
we observed that rs2296651 was associated with the in-
creased risk of HBV infection. On the other hand, under
the dominant genetic inheritance model, we observed
that rs2296651 was protective of HBV infection. Several
studies have indicated that variants of rs2296651 either
increases an individual’s susceptibility to HBV infection
and/or its complications, makes resolution/viral clear-
ance of the infection faster or improves the prognostic
outcome of cirrhosis and HCC [15, 19–22]. The evi-
dence of the transferability of rs2296651 associated with
HBV infection has been demonstrated among the Han
population [15], Taiwanese [24] and Vietnamese [19].
However, unlike our results, rs2296651 [(c.800C > T)
(S267F)] has been associated with reduced HBV infec-
tion and associated hepatic complications [25]. Among
the population of Thailand, the rs2296651 SNP variant
was associated with inactive and non-infectious CHB
and viral clearance among HBV infected persons [22].
Table 4 Odds ratios and P-values of SLC10A1 gene polymorphism under recessive, dominant, co-dominant and additive models of
inheritance
Model Alleles aOR (95% CI) bOR (95% CI)
rs2296651
Recessive Model mt/wt CT + wt/wt TT 1 (reference) 1 (reference)
mt/mt CC n/a 2.70 (0.29–24.78)
Dominant Model mt/wt TC +mt/mt TT 1 (reference) 1 (reference)
wt/wt CC 0.18 (0.07–0.44) * 1.55 (0.70–3.43)
Co-dominant model wt/wt CC +mt/mt TT 1 (reference) 1 (reference)
mt/wt TC 5.2 (2.1–12.8) * 0.85 (0.4–1.6)
Additive model 1 mt/wt TC 1 (reference) 1 (reference)
mt/mt TT 5.23 (2.09–13.11) * 0.49 (0.20–1.16)
rs61745930
Additive Model wt/wt TT 1 (reference) 1 (reference)
mt/mt CC 1.5 (0.7–3.2) 0.80 (0.4–1.6)
rs4646287
Recessive Model mt/wt TC + wt/wt TT 1 (reference) 1 (reference)
mt/mt TT n/a n/a
Dominant Model mt/wt TC +mt/mt TT 1 (reference) 1 (reference)
wt/wt CC 0.81 (0.35–1.85) 1.31 (0.53–3.24)
Co-dominant model wt/wt CC +mt/mt TT 1 (reference) 1 (reference)
mt/wt CT 1.10 (0.50–2.4) 0.96 (0.4–2.2)
Additive model 1 mt/wt TC 1 (reference) 1 (reference)
mt/mt TT 1.34 (0.58–3.10) 0.65 (0.25–1.66)
mt mutant type, wt wild type, Highlighted values represent statistically significant values. CI-confidence interval; “*” represent statistically significant model, p f <
0.05. aOR- odds ratios for controls vs cases; bOR- odds ratios HBeAg positive and HBeAg negative
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These findings indicate that although variants of
rs2296651 are associated with HBV infection, the defin-
ition of the risk variant may be dependent on the genetic
architecture of the population as well as the environ-
mental agents identified as risk factors for HBV
infection.
The study has some limitations that should be ac-
knowledged. The sample of the study was small which
may affect power replication of the odds of NTCP poly-
morphic variants associated with HBV infection. Also,
the study was localized, and generalization of findings
should be done with caution, and therefore recommend
replication studies in other parts of the country consid-
ering the limitation of this study. Although further stud-
ies are required, we have demonstrated the feasibility of
the association of rs2296651 with HBV infection in the
Ghanaian population and our findings are congruent
with previous reports among the Asian populations.
Conclusion
The study highlights some polymorphism proof that var-
iants of rs2296651, rs61745930, and rs4646287 exist in
HBV-infected individuals in Ghana. Although, variant
rs2296651 was found to be associated with HBV infec-
tion. Polymorphisms in SLC10A1 is not associated with
HBV infectivity among the Ghanaian population. Fur-
ther investigation is warranted to assess the predispos-
ition role of the relationship between rs2296651 and
HBV infectivity.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12985-020-01376-0.
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antigen/antibody profiling.
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using the PCR-RFLP. Figure S1 shows the gel bands for the SNP
rs2296651 obtained using the PCR-RFLP. MM = the molecular marker or
ladder; NC = the negative control; C (200 bp), T (120 bp). Samples 51–60
are cases and samples 291–300 are controls.
Additional file 3: Figure S2. Gel bands for the SNP rs61745930
obtained using the PCR-RFLP. Figure S2 shows the gel bands for the SNP
rs61745930 obtained using the PCR-RFLP. MM = the molecular marker or
ladder; NC = the negative control; C (400 bp), T (250). Ca = Cases and Co =
Controls. Samples 22–25, 27, 30 and 33 are cases and samples 243,
249,252, 318, 320–322 are controls.
Additional file 4: Figure S3. Gel bands for the SNP rs4646287 obtained
using the PCR-RFLP. Figure S3 shows the gel bands for the SNP
rs4646287 obtained using the PCR-RFLP. MM = the molecular marker or
ladder; C (240 bp), T (140). Samples 35–46 are cases; and samples 201–
205 plus 286–290 are controls.
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